embecta names new Chairman of the Board and Lead Independent Director

embecta (Nasdaq: EMBC) announced board leadership changes effective February 11, 2026: Devdatt "Dev" Kurdikar was elected Chairman of the Board and Dr. Claire Pomeroy was elected Lead Independent Director.

Rhea-AI Summary

embecta (Nasdaq: EMBC) announced board leadership changes effective February 11, 2026: Devdatt "Dev" Kurdikar was elected Chairman of the Board and Dr. Claire Pomeroy was elected Lead Independent Director. These changes follow the retirement of LTG (Ret.) David F. Melcher.

Kurdikar joins as chairman after serving as president and CEO of a diabetes care spinoff since 2022. Dr. Pomeroy will continue to chair the Corporate Governance and Nominating Committee and serve on the Technology, Quality and Regulatory Committee.

Positive

• Board leadership clarified with Dev Kurdikar named Chairman effective Feb 11, 2026
• Dr. Claire Pomeroy appointed Lead Independent Director and retains committee chair role

Negative

• Previous Non-Executive Chairman LTG (Ret.) David Melcher retired due to outside commitments

Argus Feb 12 session

-0.60% close to close Open Argus

Details

News Market Reaction – EMBC

On Feb 12, the first trading day after this news, EMBC closed 0.60% below the previous close.

Data tracked by StockTitan Argus for the Feb 12 session.

Market Context

This announcement details embecta’s board leadership transition, naming the CEO as Chairman and appo...

Analysis

This announcement details embecta’s board leadership transition, naming the CEO as Chairman and appointing a Lead Independent Director with ongoing committee responsibilities. It follows earlier disclosures in November 2025 about expected leadership changes and coincides with recent earnings and dividend declarations on Feb 5, 2026. Investors may focus on how this governance structure supports the company’s shift toward a broader medical supplies role and how board oversight interacts with previously outlined financial guidance and operational priorities.

Key Figures

Legacy duration: 100 years Independence period: nearly four years Devdatt Kurdikar age: 57 +1 more

Legacy duration

100 years

embecta’s insulin delivery legacy

Independence period

nearly four years

Time since launch as an independent company

Devdatt Kurdikar age

57

Age of newly appointed Chairman and CEO

Claire Pomeroy age

70

Age of new Lead Independent Director

Historical Context

5 past events · Latest: Feb 05

5 events

1. Feb 05

   Quarterly earnings

   24h Move

   -7.8%

   Reported fiscal Q1 2026 financial results and held earnings call.

2. Feb 05

   Dividend declaration

   24h Move

   -7.8%

   Announced $0.15 per share quarterly cash dividend and key dates.

3. Jan 22

   Earnings date notice

   24h Move

   -2.0%

   Set date and details for upcoming fiscal Q1 2026 results call.

4. Dec 18

   Conference participation

   24h Move

   +0.3%

   Announced presentation at J.P. Morgan 2026 Healthcare Conference.

5. Nov 25

   Earnings & guidance

   24h Move

   -7.2%

   Reported Q4/FY2025 results and issued initial FY2026 financial guidance.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

lead independent director, corporate governance and nominating committee, spinoff

3 terms

lead independent director financial

"elected Devdatt “Dev” Kurdikar as Chairman of the Board and Dr. Claire Pomeroy as Lead Independent Director, effective"

A lead independent director is a board member who is not part of company management and is chosen to coordinate and represent the other independent directors, often running sessions without the CEO, helping set meeting agendas, and serving as a liaison between shareholders and the board. For investors, this role signals stronger, more balanced oversight—like a neutral referee who helps ensure decisions are fair, transparent and focused on protecting shareholder interests.

corporate governance and nominating committee financial

"she will continue to chair the Corporate Governance and Nominating Committee and serve on the Technology, Quality and"

A corporate governance and nominating committee is a group of independent board members who set rules for how a company is run and choose or vet candidates for the board and senior leadership. Think of them as the company’s rulebook authors and hiring panel for its top oversight team; their choices and policies influence management accountability, risk oversight and investor confidence, so investors watch them for signs of strong leadership and transparency.

spinoff financial

"became the President and Chief Executive Officer of the company and a member of its Board of Directors upon completion of its spinoff from BD in 2022."

A spinoff is when a company separates part of its business into a new, independent company and gives existing shareholders shares in that new business. For investors, it matters because the move can clarify what each business is worth, let the separate companies focus on their own goals, and change risk and return — similar to converting one mixed-use property into two specialized apartments that may attract different buyers and rents.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PARSIPPANY, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta”) (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that the Board of Directors (the “Board”) of embecta has elected Devdatt “Dev” Kurdikar as Chairman of the Board and Dr. Claire Pomeroy as Lead Independent Director, effective immediately. These changes follow the previously announced retirement of LTG (Ret.) David F. Melcher, Non-Executive Chairman of the Board due to several commitments outside of his service to the Company.

Kurdikar, 57, joined BD (Becton, Dickinson and Company) in 2021 to lead the diabetes care business and became the President and Chief Executive Officer of the company and a member of its Board of Directors upon completion of its spinoff from BD in 2022. He is also a member of the Board of Directors of Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), AdvaMed (Advanced Medical Technology Association) and LMG Holdings (a portfolio company of The Riverside Company).

“Through the combined efforts of our employees around the world, embecta has come a long way since our launch as an independent company nearly four years ago,” said Kurdikar. “I am honored that my fellow Board members have placed their faith in me to continue to drive this progress while leading our transformation into a more broad-based medical supplies company.”

Dr. Pomeroy, 70, has been a member of the embecta Board of Directors since its inception in 2022. In addition to her role as Lead Independent Director, she will continue to chair the Corporate Governance and Nominating Committee and serve on the Technology, Quality and Regulatory Committee. Since 2013, she has served as President of the Albert and Mary Lasker Foundation, a private foundation that seeks to improve health by accelerating support for medical research through recognition of research excellence, public education and advocacy. She is also a director of Haemonetics Corporation and serves on the Board of Directors of the Sierra Health Foundation, Center for Women in Academic Medicine and Science, iBiology/Science Communication Lab, the Science Philanthropy Alliance, Morehouse School of Medicine, Research!America and Geisinger College of Health Sciences.

“I wish to thank the Board for their trust and support as we work together to carry out embecta’s mission to empower people with diabetes today while paving the way for a life unlimited for all,” said Dr. Pomeroy. “Between Dev’s leadership and our Board’s diversity of experience and shared sense of purpose, I have great confidence in our ability to advance embecta’s transformation and long-term success.”

About embecta 

embecta is a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, helping to improve lives through innovative solutions, partnerships, and the passion of approximately 2,000 employees around the globe. For more information, visit embecta.com or follow our social channels on LinkedIn, Facebook, and Instagram.

Contacts:
Media	Investors
Christian Glazar	Pravesh Khandelwal
Sr. Director, Corporate Communications	VP, Head of Investor Relations
908-821-6922	551-264-6547
Contact Media Relations	Contact IR

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Who is the new Chairman of embecta (EMBC) and when did the appointment take effect?

Devdatt "Dev" Kurdikar is the new Chairman, effective February 11, 2026. According to embecta, he joined BD in 2021, led the diabetes care business, and became president and CEO of the spinoff in 2022, bringing healthcare leadership experience to the board.

What role will Dr. Claire Pomeroy hold on embecta's board (EMBC) after February 11, 2026?

Dr. Claire Pomeroy will serve as Lead Independent Director and continue to chair the Corporate Governance and Nominating Committee. According to embecta, she will also remain on the Technology, Quality and Regulatory Committee, maintaining governance and oversight responsibilities.

Why did embecta (EMBC) change its board leadership on February 11, 2026?

The board changes followed the retirement of LTG (Ret.) David F. Melcher due to outside commitments. According to embecta, the appointments were made immediately to ensure leadership continuity and support the company’s transformation into a broader medical supplies company.

How might Dev Kurdikar's background influence embecta's (EMBC) strategic direction?

Kurdikar’s experience leading a diabetes care spinoff and serving as president and CEO suggests operational and industry expertise. According to embecta, his leadership is expected to support the company’s transformation toward a broader medical supplies focus and leverage prior diabetes-care experience.

Will the board committee roles change for embecta (EMBC) after these appointments?

Dr. Pomeroy will continue chairing the Corporate Governance and Nominating Committee and serve on Technology, Quality and Regulatory. According to embecta, these committee assignments remain in place to preserve governance oversight during the leadership transition.